Key statistics
As of last trade, InnoCare Pharma Ltd (33C:STU) traded at 1.26, 48.24% above the 52 week low of 0.85 set on Apr 08, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 1.26 |
|---|---|
| High | 1.28 |
| Low | 1.26 |
| Bid | 1.30 |
| Offer | 1.34 |
| Previous close | 1.20 |
| Average volume | 0.00 |
|---|---|
| Shares outstanding | 1.76bn |
| Free float | 1.20bn |
| P/E (TTM) | -- |
| Market cap | 25.21bn HKD |
| EPS (TTM) | -0.1411 HKD |
Data delayed at least 15 minutes, as of Feb 27 2026.
More ▼
Announcements
- InnoCare’s next-generation TRKi Zurletrectinib Receives Priority Review for the Treatment of Pediatric Patients with Solid Tumors in China
- InnoCare Announces Key Developments of Critical Clinical Studies
- InnoCare Announces First Patient Dosed in the Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China
- InnoCare Announces IND Approval to Initiate Clinical Trial of VAV1 Degrader ICP-538 in China
- Study Results of Novel TYK2 Inhibitor Soficitinib in Patients with AD Published by JAMA Dermatology
- InnoCare Announces NMPA Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Cutaneous Lupus Erythematosus
- InnoCare Announces Approval of Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China
- InnoCare Announces Achievement of Primary Endpoint in Phase IIb Study of Orelabrutinib for SLE and Approval of Phase III Clinical Trial
- InnoCare Announces Approval of the Next-Generation TRK Inhibitor Zurletrectinib in China
- Over 20 Studies of InnoCare’s Orelabrutinib Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)
More ▼
